Trusted Resource for Clinical Trials, Protocols & Progress
Oncology trials in Europe face specific challenges:
Recruitment: Competition among multiple oncology trials in major cancer centers
Ethics: Balancing patient risk with access to potentially life-saving therapies
Costs: Oncology trials are resource-heavy, requiring advanced imaging, biomarker testing, and complex monitoring
Sponsors should: (1) integrate decentralized tools into protocol design; (2) validate digital health systems; (3) train staff on remote monitoring; (4) strengthen site infrastructure; (5) ensure HIPAA compliance in remote data collection; (6) prepare contingency plans for disruptions; (7) harmonize global trial strategies; and (8) maintain transparent communication with FDA on novel trial designs.
Click to read the full article.
The regulatory approval and conduct of Phase 1 trials in India are governed by the Central Drugs Standard Control Organization (CDSCO) and outlined in the NDCTR 2019. Historically, India restricted Phase 1 trials of foreign molecules due to safety and ethical concerns. However, these limitations have been relaxed in recent years, particularly for drugs intended for life-threatening or rare diseases.
Click to read the full article.
Rare disease research often requires:
Click to read the full article.
Sponsors should: (1) embed ALCOA+ principles into SOPs; (2) validate all electronic systems; (3) conduct routine audits of CROs and sites; (4) train staff in GCP and data integrity; (5) implement robust SDV strategies; (6) maintain contemporaneous documentation; (7) monitor audit trails; (8) reconcile discrepancies promptly; (9) ensure eTMFs are inspection-ready; and (10) maintain CAPA programs for deficiencies.
Click to read the full article.
Rare disease trials often face:
Geographic dispersion of patients across multiple EU states
Regulatory heterogeneity despite harmonization efforts
High trial costs due to individualized therapies
The regulatory framework for generic drug development in India is primarily governed by the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules (NDCTR), 2019. For the clinical component, BA/BE studies are reviewed and approved by CDSCO, and conducted in accordance with Schedule Y and ICH E6 (GCP) principles.
Click to read the full article.
Safety reporting varies by context:
Click to read the full article.
Sponsors should: (1) validate all digital tools; (2) prepare clear SOPs for decentralized activities; (3) train staff and patients; (4) ensure HIPAA and Part 11 compliance; (5) maintain robust vendor oversight; (6) use hybrid models to balance efficiency and oversight; (7) engage FDA early on novel designs; (8) implement risk-based monitoring; and (9) maintain inspection-ready documentation at all times.
Click to read the full article.
Rare disease, pediatric, and ATMP trials often carry higher risk, requiring increased insurance premiums. Decentralized trials with direct-to-patient IMP delivery may also raise insurer concerns, necessitating careful policy negotiation.
Click to read the full article.
